Breaking microbial drug resistance through copper sequestration
The Problem
The Solution
The Opportunity
According to the CDC, antibiotic-resistant pathogens cost the U.S. healthcare system $21B-$34B yearly, resulting in more than eight million additional hospital days annually. Staphylococcus aureus and Streptococcus pneumoniae are amongst the worst offenders, leading to more than two million global deaths per year.
Worldwide, antibiotics represent a market around ~$50B with an expected growth of 5% through 2030. Our technology is disruptive because it can be produced as cheaply as conventional antibiotics without the imminent threat of losing effectiveness.
Status
This technology can kill 99+% of MRSA and Streptococcus pneumoniae in 4 hours and is effective as an inhalant against a lethal dose of Streptococcus pneumoniae pneumonia in a mouse infection model after just one dose. It is well tolerated in animal models, and the preparation of the active agent is straightforward to scale from laboratory to production. Further studies evaluate and support the efficacy of our approach are ongoing.
The intellectual property is covered through a patent for our core technology and derivatives that will be subject to further filings.
Meet the Team
MIchael D.L. Johnson PhD
College Of Medicine - Tucson
Peter Nestler PhD
Tech Launch Arizona
Contact us today.
